Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study

BMC Medicine

Hsing-Yi Chang³  Shu-Han Yu⁴  Hsin-Ni Tsai³  Chih-Cheng Hsu²  Shao-Yuan Chuang³  Meei-Shyuan Lee¹  Mark L Wahlqvist³ 

[1] Monash Asia Institute, Monash University, 900 Dandenong Road, Caulfield East, Victoria 3145, Australia;Department of Health Services Administration, China Medical University and Hospital, 91 Hsueh-Shih Road, Taichung, Taiwan 40402, ROC;Division of Preventive Medicine and Health Services Research, Institute of Population Health Sciences, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli, Taiwan 35053, ROC;Department of Psychiatry, Chung Shan Medical University, No. 110, Sec 1, Chien Kuo N. Road, Taichung, Taiwan 40201, ROC

关键词: Metformin;    Depression;    Mood;    Taiwan;    Neurodegenerative disease;   

Others  :  857276
DOI  :  10.1186/1741-7015-10-150

 received in 2012-05-17, accepted in 2012-11-29,  发布年份 2012

【 摘 要 】

Background

To confirm whether type 2 diabetes (T2DM) is an affective disorder (AD) precursor, and to establish possible effects of oral anti-hyperglycemic agents (OAAs).

Methods

A representative cohort of 800,000 subjects was obtained from the Taiwanese National Health Insurance database on 1 January 2000. Those with consistent data (n = 762,753) were followed up between 1 January 1996 and 31 December 2007. Over this period, we assessed the presence (n = 62,988) or absence (n = 699,795) of T2DM, and whether any OAA was used (n = 40,232) or not (n = 22,756). To compare the risk of AD by diabetic status, those with T2DM were matched for birth date and gender with those without T2DM. To assess the effect of OAAs, we considered those 50 years and over. Matched AD-free patients with T2DM on OAAs were compared with those without OAAs, for age, gender, locality, health service, Charlson Comorbidity Index. and diabetes diagnosis date to avoid immortal time bias. AD incidence densities, hazard ratios (HR) and 95% confidence intervals (CIs) were calculated.

Results

Compared with diabetes-free subjects, the HR (95% CI) for AD was 2.62 (2.31 to 2.98) for patients with T2DM who were not on OAAs, and 1.08 (0.99 to 1.18) for those who were on OAAs. The AD incidence density decreased from 91.1 to 39.4 per 10,000 person-years for patients on the combination of metformin and sulfonylurea. The HR (95% CI) for AD was 0.92 (0.59 to 1.45) for those on metformin alone, 1.08 (0.84 to 1.38) for those on sulfonylurea alone, and 0.40 (0.32 to 0.50) for the combined treatment, and the decrease was not related to sequence or insulin usage. Similar patterns were seen for incident AD exclusion for up to 3 years, although more so for bipolar than unipolar.

Conclusions

The incident AD risk is increased by 2.6-fold in T2DM, and the combination of sulfonylurea and metformin minimizes this risk.

【 授权许可】

   
2012 Wahlqvist et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Koenigsberg HW, Klausner E, Pelino D, Rosnick P, Campbell R: Expressed emotion and glucose control in insulin-dependent diabetes mellitus. Am J Psychiatry 1993, 150:1114-1115.
• [2]Stabler B, Surwit RS, Lane JD, Morris MA, Litton J, Feinglos MN: Type A behavior pattern and blood glucose control in diabetic children. Psychosom Med 1987, 49:313-316.
• [3]Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24:1069-1078.
• [4]Arroyo C, Hu FB, Ryan LM, Kawachi I, Colditz GA, Speizer FE, Manson J: Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care 2004, 27:129-133.
• [5]Engum A: The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res 2007, 62:31-38.
• [6]Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
• [7]Lustman PJ, Griffith LS, Freedland KE, Clouse RE: The course of major depression in diabetes. Gen Hosp Psychiatry 1997, 19:138-143.
• [8]Musselman DL, Betan E, Larsen H, Phillips LS: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003, 54:317-329.
• [9]Palinkas LA, Lee PP, Barrett-Connor E: A prospective study of type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med 2004, 21:1185-1191.
• [10]Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Willett WC, Ascherio A, Hu FB: Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 2010, 170:1884-1891.
• [11]Brown LC, Majumdar SR, Newman SC, Johnson JA: Type 2 diabetes does not increase risk of depression. CMAJ 2006, 175:42-46.
• [12]Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F, European Depression in Diabetes (EDID) Research Consortium: Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010, 53:2480-2486.
• [13]Nouwen A, Nefs G, Caramlau I, Connock M, Winkley K, Lloyd CE, Peyrot M, Pouwer F, European Depression in Diabetes Research Consortium: Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care 2011, 34:752-762.
• [14]Nefs G, Pouwer F, Denollet J, Pop V: The course of depressive symptoms in primary care patients with type 2 diabetes: results from the Diabetes, Depression, Type D Personality Zuidoost-Brabant (DiaDDZoB) Study. Diabetologia 2012, 55:608-616.
• [15]Mezuk B, Eaton WW, Albrecht S, Golden SH: Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008, 31:2383-2390.
• [16]Campayo A, de Jonge P, Roy JF, Saz P, de la Camara C, Quintanilla MA, Marcos G, Santabarbara J, Lobo A: Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry 2010, 167:580-588.
• [17]Chang HY, Hsu CC, Pan WH, Liu WL, Cheng JY, Tseng CH, Bai CH, Yeh WT, Hurng BS: Gender differences in trends in diabetes prevalence from 1993 to 2008 in Taiwan. Diabetes Res Clin Pract 2010, 90:358-364.
• [18]Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H, Yeh EK: Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996, 276:293-299.
• [19]Chong MY, Tsang HY, Chen CS, Tang TC, Chen CC, Yeh TL, Lee YH, Lo HY: Community study of depression in old age in Taiwan: prevalence, life events and socio-demographic correlates. Br J Psychiatry 2001, 178:29-35.
• [20]Huang CQ, Zhang XM, Dong BR, Lu ZC, Yue JR, Liu QX: Health status and risk for depression among the elderly: a meta-analysis of published literature. Age Ageing 2010, 39:23-30.
• [21]Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
• [22]Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20. BioMed Central Full Text
• [23]Hsu CC, Wahlqvist ML, Lee MS, Tsai HN: Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011, 24:485-493.
• [24]Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN: Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 2012, 18:753-758.
• [25]Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Kohler A, Glossmann H, Schneider R, Sutherland C, Schweiger S: Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 2010, 107:21830-21835.
• [26]Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M: Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 2008, 16:168-174.
• [27]Leroy K, Ando K, Heraud C, Yilmaz Z, Authelet M, Boeynaems JM, Buee L, De Decker R, Brion JP: Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010, 19:705-719.
• [28]Cohen ST, Welch G, Jacobson AM, De Groot M, Samson J: The association of lifetime psychiatric illness and increased retinopathy in patients with type I diabetes mellitus. Psychosomatics 1997, 38:98-108.
• [29]Levesque LE, Hanley JA, Kezouh A, Suissa S: Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087.
• [30]Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008, 167:492-499.
• [31]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40:373-383.
• [32]Profile of depression in Australia [http:/ / www.health.gov.au/ internet/ main/ publishing.nsf/ content/ 8E0E3BC67E3962AFCA25712B0080235F/ $File/ nhpa2.pdf] webcite
• [33]Khazaei MR, Habibi-Rezaei M, Karimzadeh F, Moosavi-Movahedi AA, Sarrafnejhad AA, Sabouni F, Bakhti M: Microglial cell death induced by glycated bovine serum albumin: nitric oxide involvement. J Biochem 2008, 144:197-206.
• [34]Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski TM, Mehta PD, Pratico D, Zetterberg H, Blennow K: Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012, 169:523-530.
• [35]Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Luo Z, Xu H, Liao FFL: Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 2009, 106:3907-3912.
• [36]Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, Lee HB, Lyketsos C: Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008, 299:2751-2759.
• [37]Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25:2244-2248.